AUPH - Aurinia Pharma GAAP EPS of -$0.18 beats by $0.04 revenue of $34.41M beats by $6.29M

2023-05-04 06:03:45 ET

• Aurinia Pharma press release ( NASDAQ: AUPH ): Q1 GAAP EPS of -$0.18 beats by $0.04 .
• Revenue of $34.41M (+59.1% Y/Y) beats by $6.29M .
• As of March 31, 2023, Aurinia had cash, cash equivalents and restricted cash and short-term investments of $361.5 million compared to $389.4 million at December 31, 2022.
• There were approximately 1,731 patients on LUPKYNIS therapy at March 31, 2023, compared with 1,071 at March 31, 2022.
• Aurinia added 466 PSFs during the three months ended March 31, 2023, compared to 461 during the three months ended March 31, 2022, and 406 in the three months ended December 31, 2022. An increase of 1% and 15%, respectively.
• Through Friday, April 28, 2023, the Company recorded 604 PSFs since January 1, 2023.
• Conversion rates remain consistent with the prior quarter, with approximately 85% of PSFs converted to patients on therapy.
• Time to conversion remains consistent with the prior quarter, with 30- and 60-day conversion rates holding near their best levels since launch; with the large majority (61%) of patients on therapy by 20 days.
• Persistency rates at 12 months and 15 months improved over prior periods, with approximately 51% and 47% remaining on therapy, respectively. At 18 months post-treatment start, an average of approximately 41% of patients remain on treatment.
• Shares -1.71% PM.

For further details see: